ABMD News and Press, ABIOMED Inc. From 06/02/22

Generation Investment Management's 13F portfolio value decreased from $24.33B to $21.84B this quarter. They increased Equifax, Clarivate Plc, Trane Technologies, Twilio, and Salesforce while reducing Dentsply Sirona & Sensata Technologies. The top three positions are Amazon.co...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips After hitting new lows, the stock market roared back with all the major indices posting gains last week. The S&P 500 , Dow Jones Industrial Average and NASDAQ Composite ended the week up 6.6%, 6.2%, and 6.8%, respe...

Abiomed, Inc . (NASDAQ: ABMD), a leader in breakthrough heart, lung and kidney support technologies, today announced that Michael R. Minogue, Chairman, President and Chief Executive Officer, will present (live) at the William Blair 42 nd Annual Growth Stock Conference on Monday,...

Abiomed (NASDAQ: ABMD), a leader in breakthrough heart, lung and kidney support technologies, will feature the most recent Impella research and technological advances aimed at improving outcomes for acute myocardial infarction cardiogenic shock (AMICS) patients during the Society fo...

ABMD had a decent quarter where revenues grew nicely but profits languished due to sudden growth in R&D spend. Companies like ABMD have to expense R&D, which is not a problem, but a lack of profit growth isn't great given its valuation. The multiple doesn't offer much of a...

The management team at Insulet Corporation is due to report financial data for the first quarter of the company's 2022 fiscal year. Growth should come in strong, just as it has in prior years, and the long-term outlook for Insulet looks favorable. But PODD shares are far too price...

Abiomed, Inc. (ABMD) Q4 2022 Results Conference Call April 28, 2022 08:00 AM ET Company Participants Nicole Nath - Manager, Investor Relations Michael Minogue - President and Chief Executive Officer Todd Trapp - Vice President and Chief Financial Officer Conference Call Participants Matthew O...

The following slide deck was published by Abiomed, Inc. in conjunction with their 2022 Q4 earnings call. For further details see: Abiomed, Inc. 2022 Q4 - Results - Earnings Call Presentation

Abiomed press release (NASDAQ:ABMD): Q4 Non-GAAP EPS of $1.16 beats by $0.11. Revenue of $270M (+11.9% Y/Y) beats by $2.33M. For further details see: Abiomed Non-GAAP EPS of $1.16 beats by $0.11, revenue of $270M beats by $2.33M

FY 2022 Annual Revenue of $1.032 billion, Up 22% Versus Prior Year ABIOMED, Inc. (NASDAQ: ABMD), a leader in breakthrough heart, lung and kidney support technologies, today announced financial results for the quarter and fiscal year ended March 31, 2022. Financial summ...